drugset / Trial / NCT04564703
Iberdomide (Cc220) Maintenance After Asct in Newly Diagnosed MM Patients
Phase 2
Active not recruiting
160 enrolled
Stichting European Myeloma Network
EMN Research Italy Impresa Sociale Srl · collabHealt Data Specialists - HeaDS (CRO) · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a phase II study to evaluate the efficacy and safety of different doses of iberdomide continuous therapy as maintenancetreatment after transplant.
Timeline
- Start
- 2021-02-22
- Primary completion
- 2023-07-27
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Iberdomide | Small molecule | 0.75 mg | Oral |
| Subject | Iberdomide | Small molecule | 1 mg | Oral |
| Subject | Iberdomide | Small molecule | 1.3 mg | Oral |